Yungjin Pharm Co Ltd (003520) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.078x

Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) has a cash flow conversion efficiency ratio of 0.078x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.00 Billion ≈ $4.74 Million USD) by net assets (₩90.02 Billion ≈ $61.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Yungjin Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Yungjin Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 003520 current and long-term liabilities for a breakdown of total debt and financial obligations.

Yungjin Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Yungjin Pharm Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Yg Plus Inc KO:037270	0.143x
Europap Tezol Kagit Sanayi Ve Ticaret AS IS:TEZOL	-0.058x
Korea Asset In Trust Co Ltd KO:123890	0.171x
Sound Point Meridian Capital, Inc. NYSE:SPMC	0.102x
Brightstar Resources Ltd AU:BTR	-0.042x
Cantabil Retail India Limited NSE:CANTABIL	0.087x
Nextgreen Global Bhd KLSE:7241	0.093x
Voyager Therapeutics Inc NASDAQ:VYGR	-0.141x

Annual Cash Flow Conversion Efficiency for Yungjin Pharm Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Yungjin Pharm Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Yungjin Pharm Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩89.80 Billion ≈ $60.86 Million	₩21.74 Billion ≈ $14.73 Million	0.242x	+312.24%
2023-12-31	₩89.63 Billion ≈ $60.74 Million	₩-10.22 Billion ≈ $-6.93 Million	-0.114x	+11.70%
2022-12-31	₩89.87 Billion ≈ $60.90 Million	₩-11.61 Billion ≈ $-7.87 Million	-0.129x	-261.92%
2021-12-31	₩104.89 Billion ≈ $71.08 Million	₩8.37 Billion ≈ $5.67 Million	0.080x	-37.03%
2020-12-31	₩114.43 Billion ≈ $77.55 Million	₩14.50 Billion ≈ $9.82 Million	0.127x	+57.98%
2019-12-31	₩115.75 Billion ≈ $78.44 Million	₩9.28 Billion ≈ $6.29 Million	0.080x	+602.43%
2018-12-31	₩111.61 Billion ≈ $75.63 Million	₩1.27 Billion ≈ $863.49K	0.011x	-56.66%
2017-12-31	₩119.65 Billion ≈ $81.08 Million	₩3.15 Billion ≈ $2.14 Million	0.026x	-10.13%
2016-12-31	₩106.17 Billion ≈ $71.95 Million	₩3.11 Billion ≈ $2.11 Million	0.029x	-66.56%
2015-12-31	₩100.42 Billion ≈ $68.06 Million	₩8.80 Billion ≈ $5.96 Million	0.088x	+42.11%
2014-12-31	₩100.79 Billion ≈ $68.30 Million	₩6.22 Billion ≈ $4.21 Million	0.062x	+6.13%
2013-12-31	₩102.45 Billion ≈ $69.43 Million	₩5.95 Billion ≈ $4.03 Million	0.058x	--

About Yungjin Pharm Co Ltd

KO:003520 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$217.03 Million

₩320.24 Billion KRW

Market Cap Rank

#16256 Global

#675 in Korea

Share Price

₩1751.00

Change (1 day)

-1.07%

52-Week Range

₩1700.00 - ₩2360.00

All Time High

₩17500.00